top of page

Mwandishi:

Dkt. Mercy M, CO

Mhariri:

Dkt. Sospeter B, MD

kirusi mumps-ulyclinic

Ezogabine ni moja kati ya dawa inayotumika kukinga na kupunguza degedege linaloanzia sehemu moja ya ubongo.


Majina ya kibiashara


Majina mengine ya kibiashara ya Ezogabine ni;


  • Potiga


Ezogabine ipo kundi gani la dawa?


Ezogabine ni dawa iliyo katika kundi la Anticonvulsants, Neuronal potassium.


Fomu


Dawa hii ipo katika fomu ya kidonge


Uzito


Ezogabine ina uzito ufuatao;


Kidonge

  • 50mg

  • 200mg

  • 300mg

  • 400mg


Ezogabine hutibu nini?


Hutumika kutibu degedege linaloanzia sehemu moja ya ubongo


Namna inavyofanya kazi yake


Ezogabine hufahamika kufanya kazi kwa kufungua milango ya mishipa ya fahamu ya potassium yenye jina la Kv7.2/7.3, mlango unaofanya kazi ya kutengeneza umeme wa mishipa ya fahamu na kudhibiti uamshwaji wa chembe hai. Licha ya kufanya kazi na mlango huo, dawa hii pia hudhuru risepta GABA, mlango mkuu wa kuzuia uamshwaji wa chembe hai za mfumo wa kati wa fahamu na hivyo kuwa na uwezo w akudhibiti degedege.


Ufyozwaji wa dawa


Ufyozwaji wa dawa hii hufanyika kwenye mfumo wa chakula, kiwango cha dawa kinachoonekana kwenye damu ni hadi 60% na huchukua masaa 0.5-2 dawa kuonekana kwenye damu baada ya mtu kumeza dawa.


Mwingiliano na chakula


Dawa hii inaweza kutumika mtu akiwa amepata chakula au akiwa hajapata chakula.


Wagonjwa wasiopaswa kutumia


  • Wagonjwa wenye mzio wa Ezogabine

  • Wagonjwa wenye mzio wa Neuronal potassium


Utoaji taka mwilini


Asilimia themanini na tano (85%) ya dawa hii hutolewa njee kwa njia ya mkojo na asilimia kumi nan ne (14%) hutolewa kwa njia ya haja kubwa.

Matumizi kwa mama mjamzito


Tafiti zinaonesha kuwa tahadhari kubwa inatakiwa wakati mama anatumia dawa hii kwani inaweza kuleta madhara kwa mtoto aliyeko tumboni.


Matumizi kwa mama anayenyonyesha


Hakuna tafiti zinazoonesha kama dawa inatolewa njee kupitia maziwa ya mama na kama ina madhara kwa mtoto na katika uzalishaji wa maziwa hivyo tahadhari inatakiwa wakati mama anatumia dawa hii.


Dawa zenye muingiliano na Ezogabine


Dawa zenye mwingiliano mkali na hivyo kutofaa kutumika pamoja na Ezogabine;

  • Dofetilide

  • Entrectinib

  • Fexinidazole

  • Glasdegib

  • Hydroxychloroquine sulfate

  • Inotuzumab

  • Ivosidenib

  • Lefamulin

  • Ondansetron

  • Panobinostat

  • Pitolisant

  • Ribociclib

  • Umeclidinium bromide/vilanterol ya kuvuta kwa pumzi

  • Vilanterol/fluticasone furoate ya kuvuta kwa pumzi


Dawa zinazoweza kutumika na Ezogabine chini ya uangalizi;

  • Amiodarone

  • Amitriptyline

  • Artemether/lumefantrine

  • Asenapine

  • Azithromycin

  • Bedaquiline

  • Brexanolone

  • Chlorpromazine

  • Ciprofloxacin

  • Citalopram

  • Clarithromycin

  • Droperidol

  • Erythromycin base

  • Fluconazole

  • Fluoxetine

  • Foscarnet

  • Fostemsavir

  • Gemifloxacin

  • Gemtuzumab

  • Goserelin

  • Haloperidol

  • Histrelin

  • Ibutilide

  • Iloperidone

  • Indapamide

  • Isradipine

  • Lapatinib

  • Lemborexant

  • Lenvatinib

  • Leuprolide

  • Levofloxacin

  • Lopinavir

  • Lumefantrine

  • Maprotiline

  • Mefloquine

  • Methadone

  • Mifepristone

  • Moxifloxacin

  • Octreotide

  • Ofloxacin

  • Quinidine

  • Quinine

  • Ritonavir

  • Ziprasidone


Dawa zenye mwingiliano mdogo Ezogabine;

  • Carbamazepine

  • Chloroquine

  • Clonazepam

  • Lamotrigine

  • Phenytoin

  • Valproic acid


Maudhi madogo ya Ezogabine


  • Mwili kuchoka

  • Kushindwa kulala vizuri

  • Homa

  • Kizunguzungu

  • Maumivu ya kichwa

  • Somnolence

  • Kupoteza hamu ya kula

  • Kuharisha

  • Kchefuchefu

  • Kutapika

  • Ataxia

  • Kuchanganyikiwa

  • Maumivu ya kifua

  • Kupata ganzi

  • Sindromu ya Stevens Johnson

  • Diplopia



Ufanye nini kama utasahau kutumia dozi yako?


Ni muhimu kutumia dozi kwa wakati sahihi, kama umesahau kutumia dozi yako wasiliana na daktari au mfamasia wako akupe maelekezo sahihi ya kutumia dozi inayofuata.

13 Juni 2023 19:18:46

Dawa Ezogabine

Imeboreshwa,

5 Oktoba 2021 17:29:44

Dawa yoyote ni sumu, usitumie dawa pasipo ushauri wa daktari kuepuka madhara kwenye ogani mbalimbali kama figo na ini. Matumizi ya dawa pasipo ushauri wa daktari unaweza kusababisha madhara na usugu wa vimelea vya maradhi kwenye dawa.

ULY CLINIC inakushauri siku zote uwasiliane na daktari wako kwa ushauri na tiba kabla ya kuchukua hatua yoyote ile baad aya kusoma makala hii.

Kupata ushauri zaidi na tiba kutoka kwa daktari wa ULY CLINIC bofya Mawasiliano yetu au Pata tiba.

Rejea za mada hii:

  1. Bäck SE, et al. Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab Invest. 1989 Nov;49(7):641–646.

  2. Bax RP, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):311–320.

  3. Burman LA, et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991 Feb;27(2):219–224.

  4. Christensson BA, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532–1537. 

  5. DAVIES DF, SHOCK NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950 May;29(5):496–507.

  6. Douglas JG, et al. The pharmacokinetics of cefuroxime in the elderly. J Antimicrob Chemother. 1980 Jul;6(4):543–549.

  7. Granerus G, et al. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest. 1981 Oct;41(6):611–616.

  8. Harrison MP, et al. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):265–277. 

  9. Jones RN, et al. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):9–29. 

  10. Krutzén E, et al. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 1984 Dec;104(6):955–961.

  11. Ljungberg B, et al. Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis. 1987 Mar-Apr;9(2):250–264.

bottom of page